Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to ...

In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...

Analysts called the data “very competitive” but raised questions about safety. Merck gained ownership of the ADC when it ...

Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and ...

Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...

By speeding lifesaving drugs’ way to market and focusing on the underlying causes of disease, the pathway has helped save ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...

Ionis Pharmaceuticals is advancing the investigational RNA-targeted therapy olezarsen for the treatment of familial ...

Not developing potency assays and gaining knowledge about MOAs early in the drug development process not only can break ATMP ...

In recent months Novo Nordisk has invested several billions of dollars to boost its manufacturing capacity—including its ...

The program has recently become controversial as a number of high-profile advanced approvals were granted only for the drugs ...